首页>投融资
修实生物
PreA轮
修实生物医药(南通)有限公司是一家以合成生物学技术为核心的蛋白质工程药物研发及生产企业,采用具有自主知识产权的多尺度基因元件理性设计平台,提供绿色、低碳、高效的生物智造解决方案。修实生物核心技术团队由合成生物学、制药和工程学领域的博士、大学教授和行业专家组成,具备丰富的药物开发经验。产品管线以新型药物为特色,包括多肽、胰岛素类似物、细胞因子等重组蛋白、多肽耦联药物(PDC)、纳米抗体(VHH)等。
基本信息
-
公司全称修实生物医药(南通)有限公司
-
类型合成生物学平台技术研发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址江苏省南通市崇川区唐闸镇街道永福路109号3幢101室
-
联系电话15618516980
-
邮箱1434219749@qq.com
-
成立时间2020-10-13
投融资
-
2024-10-08PreA轮7700万人民币金雨茂物华泰紫金投资小饭桌创投创景基金南通修实歌路资本
-
2023-08-07天使轮数千万人民币拾萃资本
-
2023-08-07天使轮数千万人民币拾萃资本领路资本
相关投融资企业
上市后再融资
Neurogene Inc(Neoleukin Therapeutics, Inc.~2023-12-06)前身为6175813加拿大公司(6175813 Canada Inc.)。该公司根据加拿大商业公司法,于2003年12月26日注册成立,办公地点在加拿大不列颠哥伦比亚省的温哥华市。
该公司是一家临床阶段制药公司,致力于发现和开发新的候选药物来治疗炎症和癌症。该公司的主要焦点是针对SHIP1 的抗炎候选产品,这是一个重要的细胞信号传导途径(被称为PI3K途径)免疫细胞的关键调节。该公司的先导候选产品——AQX -1125 可以激活SHIP1,并显示了其广泛的抗炎活性。作为剂量为每日一次的口服产品,AQX-1125至今已在100多个项目中成功完成三项临床试验。公司目前正在进行两个不同的二期临床试验,其一针对慢性阻塞性肺疾病,其二针对膀胱疼痛综合征/间质性膀胱炎。
上市后再融资
Ondine Biomedical Inc develops and markets topical, non-antibiotic treatments for infectious disease using photodynamic therapy as a platform technology. The Company is seeking to market a treatment for oral infectious disease.In September 2010, the company announced it was to change its name from Ondine Biopharma to Ondine Biomedical. The change was subject to approval from the Toronto Stock Exchange. In October 2010, the company changed its name, following approval from the Toronto Stock Exchange.By February 2003, Ondine had offices and research operations in Seattle, WA, and in Cincinnati, OH. At that time, the Company was engaged in completing a round of private seed investment, and was initiating a $5 million series-A fundraising from venture capital sources. In April 2007, Ondine's wholly owned research subsidiary was to relocate to new Bothell, Washington offices. Ondine was to close its office in York, Pennsylvania. The company's sales and marketing functions were to b
收并购
ImmPACT Bio USA Inc is a clinical-stage company intended to discover transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's product assures tumor specificity by inducing cytotoxicity only upon engagement of the CAR-T cell with a tumor cell, but not with any normal cell, enabling doctors to differentiate cancerous from noncancerous tissues that affect the treatment thereby mitigating the safety risks associated with current CAR-T technologies..In January 2022, ImmPACT Bio USA Inc had closed $111 million in Series B financing.In August 2020, the company closed US$ 18 million equity financing round, raised US$ 18 million in Series A financing